Vesa Lindström

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · New England Journal of Medicine · 2023 · 291 citations · Full text

Medicine, Hematology, Oncology +16

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht et al. · The Lancet Oncology · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht et al. · Blood · 2023 · 40 citations · Full text

Medicine, Hematology, Oncology +7

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Othman Al‐Sawaf, Janina Stumpf, Can Zhang et al. · New England Journal of Medicine · 2025 · 35 citations

Medicine, Immunology, Oncology +16

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · Blood · 2021 · 33 citations

Medicine, Oncology, Pharmacotherapy +14